Bellevue Life Sciences Acquisition Corp. Common Stock (BLAC) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Bellevue Life Sciences Acquisition Corp. Common Stock stock forecast from 0 analysts, the average analyst target price for Bellevue Life Sciences Acquisition Corp. Common Stock is not available over the next 12 months. Bellevue Life Sciences Acquisition Corp. Common Stock’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bellevue Life Sciences Acquisition Corp. Common Stock is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Bellevue Life Sciences Acquisition Corp. Common Stock’s stock price was USD 11.28. Bellevue Life Sciences Acquisition Corp. Common Stock’s stock price has changed by -3.26% over the past week, -0.62% over the past month and +6.47% over the last year.
No recent analyst target price found for Bellevue Life Sciences Acquisition Corp. Common Stock
No recent average analyst rating found for Bellevue Life Sciences Acquisition Corp. Common Stock
Company Overview Bellevue Life Sciences Acquisition Corp. Common Stock
Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC. Read Less
Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the health...Read More
Frequently Asked Questions About Bellevue Life Sciences Acquisition Corp. Common Stock (BLAC) Stock
Stock Target Advisor's fundamental analysis for Bellevue Life Sciences Acquisition Corp. Common Stock's stock is Very Bearish.
Unfortunately we do not have enough data on BLAC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BLAC's stock to indicate what its average analyst target is.
BLAC stock's Price/Earning ratio is 540.50.
Our analysis grades BLAC stock's Price / Earning ratio at F. This means that BLAC stock's Price/Earning ratio is above 90% of the stocks in the Shell Companies sector in the NSD exchange.
Based on this BLAC may be a overvalued for its sector.
The last closing price of BLAC's stock was USD 11.28.
The most recent market capitalization for BLAC is USD 0.05B.
Unfortunately we do not have enough analyst data on BLAC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bellevue Life Sciences Acquisition Corp. Common Stock's stock.
As per our most recent records Bellevue Life Sciences Acquisition Corp. Common Stock has 0 Employees.
Bellevue Life Sciences Acquisition Corp. Common Stock's registered address is 10900 NE 4th Street, Bellevue, WA, United States, 98004.
You can get more information about it from Bellevue Life Sciences Acquisition Corp. Common Stock's website at https://www.bellevuespac.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Bellevue Life Sciences Acquisition Corp. Common Stock (BLAC) Stock
Stock Target Advisor's fundamental analysis for Bellevue Life Sciences Acquisition Corp. Common Stock's stock is Very Bearish.
Unfortunately we do not have enough data on BLAC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BLAC's stock to indicate what its average analyst target is.
BLAC stock's Price/Earning ratio is 540.50.
Our analysis grades BLAC stock's Price / Earning ratio at F. This means that BLAC stock's Price/Earning ratio is above 90% of the stocks in the Shell Companies sector in the NSD exchange.
Based on this BLAC may be a overvalued for its sector.
The last closing price of BLAC's stock was USD 11.28.
The most recent market capitalization for BLAC is USD 0.05B.
Unfortunately we do not have enough analyst data on BLAC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bellevue Life Sciences Acquisition Corp. Common Stock's stock.
As per our most recent records Bellevue Life Sciences Acquisition Corp. Common Stock has 0 Employees.
Bellevue Life Sciences Acquisition Corp. Common Stock's registered address is 10900 NE 4th Street, Bellevue, WA, United States, 98004.
You can get more information about it from Bellevue Life Sciences Acquisition Corp. Common Stock's website at https://www.bellevuespac.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLAC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
